Oral News and Research

RSS

Use of antibacterial soaps containing chemical triclocarban may harm nursing babies

A mother's prolonged use of antibacterial soaps containing the chemical triclocarban may harm nursing babies, according to a recent study from the University of Tennessee, Knoxville.

28 Jun 2013

Janssen receives complete response letter from FDA for XARELTO sNDA

Janssen Research & Development, LLC today announced the U.S. Food and Drug Administration has issued a complete response letter for the supplemental New Drug Application for XARELTO (rivaroxaban) to reduce the risk of stent thrombosis in patients with acute coronary syndrome.

28 Jun 2013

Ritalin helps improve brain function in cocaine addiction

A single dose of a commonly-prescribed attention deficit hyperactivity disorder drug helps improve brain function in cocaine addiction, according to an imaging study conducted by researchers from the Icahn School of Medicine at Mount Sinai.

28 Jun 2013

Scientists find high prevalence of HPV infection in oral, anal and penile cavities in HIV-positive men

Scientists in Barcelona have found a high presence of papillomavirus infection in oral, anal and penile cavities in HIV-positive men, particularly in the anal cavities of men who have homosexual sex. The researchers recommend routine examination of the three areas in all men, independently of their sexual behaviour.

27 Jun 2013

Edge Therapeutics announces positive preliminary results from EG-1962 study for prevention of DCI

Edge Therapeutics announced today positive preliminary results from the first human use of EG-1962, the Company's novel bioabsorbable nimodipine microparticle formulation for the prevention of delayed cerebral ischemia, a life-threatening complication of subarachnoid hemorrhage, typically resulting from a ruptured brain aneurysm or traumatic brain injury.

27 Jun 2013

MorphoSys, Celgene agree to jointly develop MOR202 for patients with multiple myeloma

MorphoSys AG and Celgene Corporation today announced an agreement to jointly develop MOR202 globally and to co-promote MOR202 in Europe.

27 Jun 2013

Covered California selects Delta Dental to offer affordable dental coverage to children

Delta Dental of California announced today its selection by Covered California as one of six companies that will make affordable dental coverage available to California children up to 19 years old in the state's health exchange.

27 Jun 2013

Mayo Clinic opens new C. difficile Clinic at Rochester campus

Clostridium difficile (C. difficile) has reached an epidemic state and is the most common infectious cause of diarrhea in hospitals. Health care providers are seeing increased severity and recurrence rates of the infection. In response, Mayo Clinic has opened a C. difficile Clinic at the Rochester campus.

25 Jun 2013

Research may lead to new screening method for oral cancer and HPV

Research being carried out at the University of Notre Dame and its affiliated Harper Cancer Research Institute may lead to the development of a rapid, cost-effective means of screening for oral cancers and the human papillomavirus.

25 Jun 2013

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced Phase 1 data from an ongoing study of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with advanced hematologic malignancies, or potentially fatal blood cancers.

25 Jun 2013

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Sanofi announced today that the first Phase 3 study results for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus.

24 Jun 2013

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin with or without oral anti-diabetic agents (OADs). Lixisenatide is for the treatment of adults with type 2 diabetes mellitus.

24 Jun 2013

Shield Therapeutics recruits patients for ST10 Phase 3 study for treating iron-deficient anaemia

Shield Therapeutics, the independent specialty mineral medicines pharmaceutical company, today announces that it has completed recruitment of patients into its pivotal Phase 3 programme of ST10 for the treatment of iron-deficient anaemia. ST10 is a novel form of ferric iron taken orally.

24 Jun 2013

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. announced that following the regulatory review process by the European Medicines Agency (EMA) and a positive opinion from the Committee for Medicinal Products for Human Use on April 25, 2013, the European Commission (EC) has granted the marketing authorization for XTANDI™ (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.

24 Jun 2013

Scientists find way to attack dangerous bacteria that cause eye infections

Much as predators attack their prey in the animal world, there are bacteria that consume and kill other bacteria. Scientists are reporting new progress in putting the predator microbes to work - to attack dangerous bacteria that cause eye infections that lead to blindness and have grown resistant to antibiotics.

21 Jun 2013

FDA approves use of Plan B One-Step pill for all women with child-bearing potential

Today, the U.S. Food and Drug Administration announced it has approved the use of Plan B One-Step (levonorgestrel) as a nonprescription product for all women of child-bearing potential.

21 Jun 2013

BerGenBio AS starts Phase 1 Clinical Trial for BGB324 oral AXL inhibitor

BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.

20 Jun 2013

Oral News and Research

Use of antibacterial soaps containing chemical triclocarban may harm nursing babies

Janssen receives complete response letter from FDA for XARELTO sNDA

Ritalin helps improve brain function in cocaine addiction

Scientists find high prevalence of HPV infection in oral, anal and penile cavities in HIV-positive men

Edge Therapeutics announces positive preliminary results from EG-1962 study for prevention of DCI

MorphoSys, Celgene agree to jointly develop MOR202 for patients with multiple myeloma

Covered California selects Delta Dental to offer affordable dental coverage to children

Mayo Clinic opens new C. difficile Clinic at Rochester campus

Research may lead to new screening method for oral cancer and HPV

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

Shield Therapeutics recruits patients for ST10 Phase 3 study for treating iron-deficient anaemia

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Scientists find way to attack dangerous bacteria that cause eye infections

FDA approves use of Plan B One-Step pill for all women with child-bearing potential

BerGenBio AS starts Phase 1 Clinical Trial for BGB324 oral AXL inhibitor

Treating bacteria with silver compounds boosts efficacy of old antibiotics

Oral probiotic supplement increases vitamin D levels in blood, says study

Ibrutinib shows remarkable promise for treatment of mantle cell lymphoma

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News